1. Home
  2. CECO vs CELC Comparison

CECO vs CELC Comparison

Compare CECO & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CECO Environmental Corp.

CECO

CECO Environmental Corp.

HOLD

Current Price

$64.74

Market Cap

3.9B

Sector

Industrials

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$65.82

Market Cap

4.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CECO
CELC
Founded
1966
2011
Country
United States
United States
Employees
1540
N/A
Industry
Pollution Control Equipment
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
4.2B
IPO Year
2002
2017

Fundamental Metrics

Financial Performance
Metric
CECO
CELC
Price
$64.74
$65.82
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
12
Target Price
$111.86
★ $156.91
AVG Volume (30 Days)
744.6K
★ 1.1M
Earning Date
10-27-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 280.56
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$73.67
N/A
Revenue Next Year
$35.70
$1,322.81
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$42.85
$45.15
52 Week High
$101.24
$151.02

Technical Indicators

Market Signals
Indicator
CECO
CELC
Relative Strength Index (RSI) 37.63 28.70
Support Level $59.46 N/A
Resistance Level $65.97 $96.39
Average True Range (ATR) 3.47 4.58
MACD -0.76 -0.94
Stochastic Oscillator 4.20 10.57

Price Performance

Historical Comparison
CECO
CELC

About CECO CECO Environmental Corp.

CECO Environmental Corp is an industrial company, serving industrial air, industrial water, and energy transition markets. It offers various engineered and configured products and solutions, including dampers and diverters, selective catalytic reduction systems, severe-service and industrial cyclones, dust collectors, thermal oxidizers, filtration systems, wet and dry scrubbers, water treatment packages, industrial silencers, etc. These products are offered through brands like Western Airducts, WK, Wakefield Acoustics, Transcend, Verantis, and others. The company's reportable segments are: Engineered Systems, which derive maximum revenue, and Industrial Process Solutions. Geographically, it derives key revenue from the U.S., followed by the Netherlands, the UK, China, and other markets.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Share on Social Networks: